<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic hand eczema</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic hand eczema</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic hand eczema</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael P Sheehan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H506386519"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hand eczema, or hand dermatitis, is a common, inflammatory disorder involving the skin of the hands [<a href="#rid1">1</a>]. The term "chronic hand eczema" is appropriate in cases that persist for more than three months or recur two or more times within a 12-month time frame [<a href="#rid2">2</a>]. Typical clinical signs include redness, thickening of the skin, scaling, edema, vesicles, areas of hyperkeratosis, cracks (fissures), and erosions  (<a class="graphic graphic_picture graphicRef50299 graphicRef95750" href="/z/d/graphic/50299.html" rel="external">picture 1A-B</a>).</p><p>Hand eczema is the most frequent occupational skin disease, especially among workers exposed to "wet work," such as health care workers, food handlers, and hairdressers. It can have profound economic consequences, including medical costs; costs associated with disability, workers' compensation, and rehabilitation; absence from work; and job loss [<a href="#rid3">3</a>]. Severe hand eczema can affect the patient's psychosocial functioning and general well-being.</p><p>This topic will review the clinical manifestations, diagnosis, and management of chronic hand eczema. Acute palmoplantar eczema, irritant contact dermatitis, and allergic contact dermatitis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">"Management of allergic contact dermatitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H506386525"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hand eczema is a common problem in the general population and especially in some categories of workers, including health care workers, hairdressers, and food handlers:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and incidence in the general population</strong> – A 2021 meta-analysis of 66 studies including nearly 570,000 individuals from the general population found an overall lifetime prevalence of 14.5 percent (95% CI 12.6-16.5 percent) [<a href="#rid4">4</a>]. The overall one-year prevalence was 9.1 percent (95% CI 8.4-9.8 percent), and the point prevalence was 4 percent (95% CI 2.6-5.7 percent). All pooled prevalences were higher among females than males. Cohort studies of adolescents and young adults followed up for approximately 15 years estimated an incidence of hand eczema of approximately 9 to 12 per 1000 person-years [<a href="#rid5">5,6</a>]. In a German study, the lifetime prevalence of hand eczema among adolescents at the age of 15 was 10.4 percent (95% CI 8.9-12.1) [<a href="#rid7">7</a>]. Based on data from 11 European studies, the overall pooled incidence of hand eczema in the general population has been estimated at 7.3 cases per 1000 person-years (95% CI 5.4-9.5) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">Hand eczema is also the most common occupational skin disease. The incidence of occupational hand dermatitis has been estimated between 0.7 and 1.5 cases per 1000 workers per year [<a href="#rid8">8</a>]. Estimated prevalence ranges between 2 and 30 percent [<a href="#rid9">9</a>]. Incidence is highest among workers performing "wet work" (eg, health care workers, food handlers, hairdressers). A Danish study of health care workers found a one-year prevalence of hand eczema of 21 percent and a lifetime prevalence of 35 percent [<a href="#rid10">10</a>]. A similar study of Hong Kong nurses found a prevalence rate of 22 percent [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">A 2022 meta-analysis of 19 studies including 15,000 hairdressers found a pooled lifetime prevalence of hand eczema of 38 percent and an overall incidence rate of 51.8 cases per 1000 person-years (95% CI 42.6-61.0) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Because these numbers represent only the cases reported, they are likely an underestimate of the true prevalence. Studies have shown that occupational hand dermatitis is often underreported. In one study involving over 2000 hairdressers with chronic hand eczema, only 21 percent had reported their hand eczema as occupational to the workers' compensation authority [<a href="#rid13">13</a>]. A similar study of health care workers found that only 12 percent reported their hand eczema [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– In a 2022, Finnish, population-based study that included 6830 individuals, hand eczema was reported in 900 individuals (13.3 percent) [<a href="#rid14">14</a>]. Strong risk factors for hand eczema included a personal history of atopic dermatitis (odds ratio [OR] 11.8, 95% CI 10.1-13.9), allergic rhinoconjunctivitis (OR 2.96, 95% CI 2.55-3.44), or asthma (OR 2.39, 95% CI 2.03-2.81).</p><p></p><p class="bulletIndent1">A 2022 analysis of data from the Netherlands LifeLines Cohort Study that included over 58,000 participants found a positive association between chronic hand eczema and female sex, atopic dermatitis, and exposure to wet activities [<a href="#rid15">15</a>]. In addition, cigarette smoking and being overweight and obese were also positively associated with having chronic hand eczema in the past year.</p><p></p><p class="bulletIndent1">In a 2022 meta-analysis of 29 observational studies, hand washing multiple times per day (8 to 10 times per day or more) was also associated with an increased risk of hand eczema (relative risk [RR] 1.48, 95% CI 1.30-1.67 for health care workers and RR 1.62, 95% CI 1.13-2.34 for non-health care workers) [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H506386531"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of hand eczema is multifactorial and involves both genetic and environmental factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic susceptibility</strong> – There is an association between the susceptibility to hand eczema and loss-of-function mutations in the filaggrin gene (<em>FLG</em>), which is important for the integrity of the epidermal barrier [<a href="#rid17">17</a>]. Filaggrin is involved in terminal differentiation of the skin with appropriate keratin filament alignment and stratum corneum hydration. Loss-of-function filaggrin polymorphisms predispose to xerosis, ichthyosis vulgaris, and atopic eczema [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis", section on 'Epidermal barrier dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wet work</strong> – Repetitive wet work exposure is recognized as a predisposing factor for hand eczema. Water exposure for more than three hours per day can induce physiologic changes in the normal skin and increase the susceptibility to skin irritation [<a href="#rid19">19</a>]. Studies of occupational hand eczema in health care workers have found an association with hand-washing practices, such as the daily number of hand washes with soap at work and time working with disposable gloves [<a href="#rid16">16,20</a>]. However, the use of alcohol-based hand sanitizer does not seem to increase the risk of hand eczema [<a href="#rid16">16</a>]. Unprotected wet work for more than two hours a day in hairdressers has been shown to be a significant risk factor for the development of hand eczema [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritants/allergens</strong> – Irritants often play an important role in both the development and persistence of hand eczema. In addition to water, important irritants include detergents, fragrances, and preservatives in hand soaps; harsh chemicals found in common household and industrial cleaners, such as ammonia and solvents; raw fruits, vegetables, spices, and plants; and physical irritants (eg, metal tools, wood, fiberglass, dust/soil). (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent1">Hand eczema may also be a manifestation of allergic contact dermatitis, a specific T cell-mediated, delayed-type hypersensitivity reaction. Contact sensitization has been reported in over 60 percent of patients with hand eczema [<a href="#rid22">22,23</a>]. Common allergens include nickel, formaldehyde, quaternium-15, methylisothiazolinone, and fragrance mix. (See <a class="local">'Patch testing'</a> below and  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1">Chronic or recurrent hand eczema is also the most frequent clinical manifestation of contact urticaria/protein contact dermatitis (CU/PCD), a distinct type of dermatitis induced by a type I immediate hypersensitivity reaction to high molecular weight allergens, such as animal or plant proteins in previously sensitized individuals [<a href="#rid24">24,25</a>]. CU/PCD predominantly occurs in food handlers, cooks, veterinarians, or farmers [<a href="#rid26">26</a>]. Patients with CU/PCD usually have a positive prick test or specific serum immunoglobulin E (IgE) to certain foods but negative patch tests [<a href="#rid27">27,28</a>]. The reaction usually starts as an urticarial allergic response, but with repeated episodes over time, the clinical appearance is that of chronic eczema.</p><p></p><p>Frequent relapses of acute palmoplantar eczema (dyshidrotic eczema) may also result in chronic hand dermatitis lichenified. (See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p class="headingAnchor" id="H506386537"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In the acute stage, hand eczema typically presents with erythema, edema, weeping, and vesiculation  (<a class="graphic graphic_picture graphicRef95749 graphicRef82993" href="/z/d/graphic/95749.html" rel="external">picture 2A-B</a>). As lesions become subacute or chronic, the lesion morphology shifts to scaling, thickening, and fissuring of the skin  (<a class="graphic graphic_picture graphicRef59959 graphicRef116272" href="/z/d/graphic/59959.html" rel="external">picture 3A-B</a>).</p><p>Lesions are usually bilateral and may involve the palmar or dorsal surface or both. In long-standing disease, nail changes may be seen, including loss of the cuticle, thickening of the nail folds (chronic paronychia), and ridging and thickening of the nail plate  (<a class="graphic graphic_picture graphicRef95889" href="/z/d/graphic/95889.html" rel="external">picture 4</a>).</p><p>Symptoms may include itching, burning, or stinging.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical variants</strong> – Clinical variants of hand eczema include [<a href="#rid29">29,30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic, fissured hand eczema  (<a class="graphic graphic_picture graphicRef59959" href="/z/d/graphic/59959.html" rel="external">picture 3A</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent, vesicular hand eczema (dyshidrotic eczema)  (<a class="graphic graphic_picture graphicRef83056 graphicRef82783" href="/z/d/graphic/83056.html" rel="external">picture 5A-B</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperkeratotic palmar eczema, also called psoriasiform or tylotic hand dermatitis  (<a class="graphic graphic_picture graphicRef95750" href="/z/d/graphic/95750.html" rel="external">picture 1B</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Pulpitis (hyperkeratotic eczema of the fingertips)  (<a class="graphic graphic_picture graphicRef50299" href="/z/d/graphic/50299.html" rel="external">picture 1A</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Interdigital eczema  (<a class="graphic graphic_picture graphicRef83192" href="/z/d/graphic/83192.html" rel="external">picture 6</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Nummular hand eczema  (<a class="graphic graphic_picture graphicRef95890" href="/z/d/graphic/95890.html" rel="external">picture 7</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pattern and distribution of lesions</strong> – The pattern and distribution of the hand lesions may vary depending on the etiology [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Irritant contact dermatitis</strong> – Irritant contact dermatitis is variable and can involve the dorsal hands or palms. The distal aspect of the dorsum of the fingers is often involved. (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allergic contact dermatitis</strong> – Allergic contact dermatitis often involves the dorsal aspect of the hands and fingers and the volar aspect of the wrists  (<a class="graphic graphic_picture graphicRef82993" href="/z/d/graphic/82993.html" rel="external">picture 2B</a>). (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic atopic hand dermatitis</strong> – Chronic atopic hand dermatitis usually involves the dorsum of the hands and fingers  (<a class="graphic graphic_picture graphicRef82881" href="/z/d/graphic/82881.html" rel="external">picture 8</a>) and/or the side of the fingers. It presents with erythema, scaling, and fissuring. Chronic paronychia and nail dystrophy are often associated. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dyshidrotic eczema</strong> – Dyshidrotic eczema typically presents with a sudden outbreak of intensely itchy, deep-seated vesicles on the palms and lateral and dorsal aspects of the fingers  (<a class="graphic graphic_picture graphicRef116639 graphicRef112980" href="/z/d/graphic/116639.html" rel="external">picture 9A-B</a>). Frequent relapses may result in chronic hand dermatitis, characterized by erythematous, lichenified, and scaling patches or plaques with fissures  (<a class="graphic graphic_picture graphicRef82782" href="/z/d/graphic/82782.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p></p><p class="headingAnchor" id="H506386543"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>The histopathologic findings of hand eczema vary according to the stage of the disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute stage</strong> – In the acute stage, a classic, spongiotic reaction pattern is seen, including intercellular edema, microvesicle formation, and a superficial dermal infiltrate of lymphocytes, with or without eosinophils.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic stage</strong> – As the dermatosis progresses to the chronic stage, the degree of spongiosis is often mild and epidermal acanthosis, parakeratosis, and hyperkeratosis predominate, with a superficial, perivascular, lymphohistiocytic, inflammatory infiltrate.</p><p></p><p>It is important to note that psoriasiform hand dermatitis is often a histologic challenge, and biopsy often provides confusion and/or contradictory information [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H506386549"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of chronic hand eczema is based upon a detailed history, physical examination, and patch testing. A skin biopsy may be necessary to exclude other dermatoses involving the hands that may mimic chronic hand eczema. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H12329033"><span class="h2">History</span><span class="headingEndMark"> — </span>A detailed personal, occupational, and recreational history, focused on exposure to irritants and allergens, should be obtained from all patients presenting with hand eczema. Patients should be questioned about:</p><p class="bulletIndent1"><span class="glyph">●</span>Type of work or hobbies</p><p class="bulletIndent1"><span class="glyph">●</span>Potential exposures to irritants or allergens</p><p class="bulletIndent1"><span class="glyph">●</span>Duration and frequency of exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Type of personal protective equipment used </p><p class="bulletIndent1"><span class="glyph">●</span>Personal or family history of atopy, such as asthma, hay fever, allergic rhinoconjunctivitis, or childhood eczema</p><p></p><p>A detailed assessment of exposure is of key importance to plan patch and prick testing. The results of previous allergy testing, including patch testing, prick testing, and radioallergosorbent testing (RAST), should also be recorded.</p><p>Precise information regarding the onset of dermatitis, duration, associated symptoms (burning, itching, stinging, swelling), and relieving factors should be obtained. In occupational cases, patients may have a clear history of improvement on weekends and time off work.</p><p class="headingAnchor" id="H12329039"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>When examining the patient's hands, the clinician should assess the extent of hand involvement and whether the skin changes extend to the wrist, the finger webs are involved, and the nails are normal or abnormal [<a href="#rid31">31</a>]. In addition, a complete skin examination should be performed, looking for skin changes in other body areas that may be related to the hand disorder (eg, flexural dermatitis suggesting atopic dermatitis, erythematous plaques surmounted by silvery white scales suggesting psoriasis).</p><p class="headingAnchor" id="H2798480128"><span class="h2">Patch testing</span><span class="headingEndMark"> — </span>Patch testing should be considered in all patients with chronic hand eczema that does not respond to adequate treatment as well as in patients in whom contact allergy is suspected.</p><p>Common allergens associated with hand dermatitis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Preservatives</p><p class="bulletIndent1"><span class="glyph">●</span>Fragrances</p><p class="bulletIndent1"><span class="glyph">●</span>Metals (eg, nickel, cobalt)</p><p class="bulletIndent1"><span class="glyph">●</span>Rubber</p><p class="bulletIndent1"><span class="glyph">●</span>Topical antibiotics (eg, <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a>, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>)</p><p></p><p>However, the selection of substances to be tested and the relevance of positive reactions should be based on the patient's occupational or recreational exposures. </p><p>A detailed discussion of patch testing and common contact allergens is presented separately. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.) </p><p class="headingAnchor" id="H2868553292"><span class="h2">Skin prick tests and specific IgE measurement</span><span class="headingEndMark"> — </span>Prick/puncture skin tests and determination of serum food-specific IgE levels are indicated in patients with suspected contact urticaria/protein contact dermatitis (CU/PCD). (See  <a class="medical medical_review" href="/z/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy", section on 'Prick/puncture skin tests'</a> and  <a class="medical medical_review" href="/z/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy", section on 'In vitro testing'</a>.)</p><p class="headingAnchor" id="H3111758713"><span class="h2">Other laboratory tests</span><span class="headingEndMark"> — </span>Other laboratory tests include:</p><p class="bulletIndent1"><span class="glyph">●</span>A potassium hydroxide (KOH) preparation may be useful to exclude a dermatophyte infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial cultures may be useful to guide treatment in patients with clinical signs of superinfected hand eczema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A scabies preparation may be helpful to exclude <em>Sarcoptes scabiei</em> infestation.</p><p></p><p class="headingAnchor" id="H46943576"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Skin biopsy is not routinely performed in patients with hand eczema. However, in some patients, a skin biopsy for histopathologic examination may be necessary to exclude other conditions that may mimic chronic hand eczema. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H31412112"><span class="h1">ASSESSMENT OF SEVERITY</span><span class="headingEndMark"> — </span>For the management of the individual patient with chronic hand eczema, it is important that clinicians evaluate the extent and characteristics of the eruption and ask general questions about the impact of the disease on the patient's professional and everyday activity, psychosocial functioning, and general well-being.</p><p>Although infrequently used in clinical practice, several tools have been developed to assess the clinical severity of hand eczema and response to treatment [<a href="#rid33">33</a>]. They include the Hand Eczema Severity Index (HECSI) [<a href="#rid34">34</a>], the Physician Global Assessment (PGA) [<a href="#rid35">35</a>], the clinical photo guide [<a href="#rid36">36</a>], and several instruments measuring the health-related quality of life in patients with skin diseases, such as the Dermatology Life Quality Index (DLQI) [<a href="#rid37">37</a>].</p><p>The PGA is a relatively simple tool that involves the evaluation of the intensity of the skin changes and the extent of involvement [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild eczema</strong> – Mild eczema is defined by the presence of two or more mild skin changes (erythema, scaling, hyperkeratosis, lichenification, vesiculation, edema, fissures, pruritus, and pain) involving &lt;10 percent of the hand surface  (<a class="graphic graphic_picture graphicRef50299" href="/z/d/graphic/50299.html" rel="external">picture 1A</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate eczema</strong> – Moderate eczema is defined by the presence of two or more mild to moderate skin changes (erythema, scaling, hyperkeratosis, lichenification, vesiculation, edema, fissures, pruritus, and pain) involving 10 to 30 percent of the hand surface  (<a class="graphic graphic_picture graphicRef82993" href="/z/d/graphic/82993.html" rel="external">picture 2B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe eczema</strong> – Severe eczema is defined by the presence of two or more moderate to severe skin changes (erythema, scaling, hyperkeratosis, lichenification, vesiculation, edema, fissures, pruritus, and pain) involving &gt;30 percent of the hand surface  (<a class="graphic graphic_picture graphicRef59959" href="/z/d/graphic/59959.html" rel="external">picture 3A</a>).</p><p></p><p class="headingAnchor" id="H506386555"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for hand eczema includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar plaque psoriasis</strong> – Palmoplantar psoriasis presents with thick, scaly papules or plaques on an erythematous base. Lesions may be present on the palmar or dorsal surface of the hand  (<a class="graphic graphic_picture graphicRef93909" href="/z/d/graphic/93909.html" rel="external">picture 11</a>). The presence of nail pitting and/or classic, psoriatic plaques on other body sites is a clue to the diagnosis. In patients with isolated hand involvement, a skin biopsy may be helpful in rendering the correct diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar pustulosis</strong> – Palmoplantar pustulosis is a chronic, inflammatory dermatosis characterized by the development of recurrent crops of discrete, 1 to 10 mm, sterile pustules limited to the palms and/or soles  (<a class="graphic graphic_picture graphicRef94793 graphicRef82843 graphicRef94792" href="/z/d/graphic/94793.html" rel="external">picture 12A-C</a>). It is often viewed as an isolated subset of acral psoriasis. Usually, it can be differentiated from chronic hand eczema on clinical grounds. In atypical cases, a skin biopsy showing an intraepidermal pustule filled with polymorphonuclear leukocytes associated with epidermal spongiosis can clarify the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea manuum</strong> – Tinea manuum is a dermatophyte infection that typically involves one hand and presents with erythema and fine scaling of the palm. In most cases, patients have a concomitant infection of the feet and toenails  (<a class="graphic graphic_picture graphicRef57816" href="/z/d/graphic/57816.html" rel="external">picture 13</a>). A potassium hydroxide (KOH) examination of scrapings from the lesions confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scabies</strong> – Scabies is a common infestation of the skin caused by <em>S. scabiei</em> and is characterized by intense pruritus and multiple small, erythematous papules or by poorly defined, erythematous patches that develop prominent scale, crusts, and fissures (crusted scabies)  (<a class="graphic graphic_picture graphicRef51125 graphicRef114527 graphicRef114538" href="/z/d/graphic/51125.html" rel="external">picture 14A-C</a>). A scabies preparation can confirm the presence of scabies mites, eggs, or feces. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H55983597"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of chronic hand eczema involves patient education about avoidance of irritants and allergens, skin protection measures, and topical or systemic anti-inflammatory therapy [<a href="#rid38">38,39</a>]. Our approach to treatment is consistent with published international guidelines [<a href="#rid29">29,38-41</a>].</p><p class="headingAnchor" id="H319472250"><span class="h2">General principles</span></p><p class="headingAnchor" id="H86787527"><span class="h3">Patient education</span><span class="headingEndMark"> — </span>A change in behavior is an important component of the management of chronic hand eczema when irritant or allergic factors are present. Patients should be educated about the causes of hand eczema, the avoidance of potential triggers, the adoption of preventive strategies and skin protection measures, and the importance of adherence to treatment [<a href="#rid42">42</a>]. The efficacy of education programs in the prevention and management of hand eczema has been evaluated in multiple clinical trials [<a href="#rid43">43-45</a>]. In one trial, 255 health care workers with hand eczema were randomly assigned to an education program with individual counseling and usual treatment or to usual treatment alone. At follow-up, the mean score on the Hand Eczema Severity Index (HECSI) was significantly lower in the intervention group than in the control group.</p><p class="headingAnchor" id="H46944092"><span class="h3">Avoidance of irritants and allergens</span><span class="headingEndMark"> — </span>Patients should be counseled on potential triggers found within the home and work environment. Common chemical irritants include water and wet work, detergents and surfactants, solvents, oxidizing agents, acids, and alkalis. Physical irritants include metal tools, wood, fiberglass, plant parts, paper, and dust or soil. Common sources of allergens include soaps and detergents, foods, industrial solvents and oils, cement, metals, topical medications, gloves, and cosmetics  (<a class="graphic graphic_table graphicRef56218" href="/z/d/graphic/56218.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults", section on 'Common irritants'</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.)</p><p>Harsh soaps should be avoided, and hand-washing habits should be modified. Patients should wash with lukewarm water using a mild, unscented and fragrance-free bar soap or a liquid nonsoap (synthetic) detergent. Drying should be a gentle pat dry with attention to removing excess moisture from the interdigital spaces.</p><p>Hand washing and drying should be followed immediately by the application of a generous amount of heavy hand cream or ointment, such as petroleum jelly. Although less effective than ointments, lotion formulations can be used by patients who feel that ointment and thick cream are greasy and interfere with work or school activities [<a href="#rid46">46</a>]. Excessive or habitual hand washing should be discouraged. Overuse of soap and water can prevent the restoration of the epidermal barrier and healing of hand eczema. If the hands are not visibly soiled, an alcohol-based hand sanitizer can be substituted to minimize overexposure to soap and wet-to-dry cycles [<a href="#rid16">16,47,48</a>].</p><p class="headingAnchor" id="H12329398"><span class="h3">Skin protection</span><span class="headingEndMark"> — </span>Use of personal protective equipment is also paramount in the management of hand eczema:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gloves</strong> – Gloves should be worn during cooking, gardening, and cleaning to minimize exposure to irritants such as raw meat, vegetables, and chemicals.</p><p></p><p class="bulletIndent1">Vinyl or other nonlatex gloves are suitable for many routine exposures. Vinyl gloves are generally preferred to latex or rubber gloves due to the lesser presence of potential allergens. When protective gloves are to be used for intervals longer than 10 minutes, a thin cotton glove should be worn underneath. This will provide an absorbent layer and prevent sweat from irritating the skin with longer glove use. The cotton gloves can be washed and reused.</p><p></p><p class="bulletIndent1">For occupational exposures, environmental hazards need to be considered when making the choice for protective glove recommendations. The patient should be encouraged to discuss appropriate protective equipment with their employer. The material safety and data sheet (MSDS) for a given chemical can be helpful and may list appropriate glove guidelines.</p><p></p><p class="bulletIndent1">Certain materials readily penetrate various glove types, and not all gloves are suitable for all tasks. For example, acrylates that may be utilized in dentistry and orthopedics can easily penetrate many rubber and vinyl gloves. Therefore, if an individual is allergic to acrylates, a foil-type 4H chemical-resistant glove may be required under vinyl or rubber gloves [<a href="#rid49">49</a>]. It is also important that protective gloves be intact without holes, clean and dry on the inside, and the appropriate size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>"Barrier creams"</strong> – So-called "barrier creams" are formulated to mimic the intercellular lipids, which are composed of ceramides, free fatty acids, and cholesterol, with the aim to limit the penetration of hazardous chemicals into the epidermis. They can either be water repellent or oil repellent. However, their superior efficacy compared with common emollients is unproven, and they cannot be used to replace gloves and other personal protective equipment [<a href="#rid50">50-54</a>]. Nonetheless, they may be utilized to augment protection against low-grade irritants.</p><p></p><p class="headingAnchor" id="H12329411"><span class="h2">Mild to moderate disease</span></p><p class="headingAnchor" id="H3500832995"><span class="h3">Emollients/moisturizers</span><span class="headingEndMark"> — </span>We suggest frequent and liberal use of emollients and moisturizers for all patients with hand eczema. To ensure consistent use, the choice of emollients and moisturizers is based on the patient's preference and exclusion of contact sensitization to any of the components.</p><p>Moisturizers that contain humectants and emollients improve the skin barrier function of the stratum corneum. Humectants include ingredients such as <a class="drug drug_general" data-topicid="8959" href="/z/d/drug information/8959.html" rel="external">glycerin</a>, topical <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">urea</a>, and pyrrolidone carboxylic acid. The primary function of humectants is to attract water and hydrate the stratum corneum. Emollients smooth the dry, flaking skin and also provide some occlusion to prevent water loss. Petrolatum, <a class="drug drug_general" data-topicid="129549" href="/z/d/drug information/129549.html" rel="external">dimethicone</a>, and waxes are common emollient ingredients.</p><p>Moisturizers are available in various formulations, such as oil-in-water, water-in-oil, and gels, and may contain keratolytic ingredients (eg, <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">urea</a>, salicylic acid) that help reduce thickness and scaling in hyperkeratotic hand eczema.</p><p>Open-label studies have shown that the appropriate use of emollients can improve the clinical signs of hand eczema and delay relapse [<a href="#rid52">52,55,56</a>]. In a small, open-label trial, 53 patients with chronic hand eczema controlled with moisturizers only were randomized to twice-daily use of a 5% <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">urea</a> moisturizer cream or no treatment [<a href="#rid55">55</a>]. The median time to reappearance of eczema was 20 days in the moisturizer group versus two days in the no treatment group.</p><p class="headingAnchor" id="H3417192925"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>We suggest topical corticosteroids as a first-line treatment for mild to moderate hand eczema in conjunction with emollients and moisturizers:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – We typically use high-potency or super high-potency topical corticosteroids (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)). Topical corticosteroids are applied once or twice a day for two to four weeks or until a stable improvement is achieved. Emollients should be applied liberally multiple times per day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance treatment</strong> – After induction of remission, we suggest maintenance intermittent therapy with a low- to mid-potency topical corticosteroid (groups 4 to 6  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) two to three times per week (eg, every other day or during weekends) to prevent relapses. Intermittent therapy can be continued for several months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of relapses</strong> – Relapses are treated by resuming daily use of topical corticosteroids until remission. However, long-term use of topical corticosteroids (especially high- or super high-potency preparations) may induce skin atrophy, especially on the thinner skin of the dorsal hand (see  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects"</a>). Topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is an alternative to topical corticosteroids for patients with frequent relapses. (See <a class="local">'Topical calcineurin inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Although topical corticosteroids are widely used as a first-line therapy for hand eczema, data from randomized trials supporting their use are limited [<a href="#rid39">39</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial that included 125 participants with chronic hand eczema, twice-daily <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> foam was not more effective than vehicle in improving the eczema at 15 days as assessed by the investigator's rating scale [<a href="#rid57">57</a>]. The authors suggested that the emollient properties of the vehicle may have influenced the results.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an open-label, randomized trial, 120 patients with chronic hand eczema initially treated with daily <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate 0.1% fatty cream for up to nine weeks or until the dermatitis cleared were randomly assigned to a 30-week maintenance period with intermittent mometasone furoate (once daily two or three times per week) or vehicle [<a href="#rid58">58</a>]. At the end of the study, more patients were free of recurrence in the groups using mometasone furoate three or two times weekly than in the group using the vehicle (83, 68, and 26 percent, respectively).</p><p></p><p class="headingAnchor" id="H946964590"><span class="h3">Topical calcineurin inhibitors</span><span class="headingEndMark"> — </span>Topical calcineurin inhibitors can be used as a steroid-sparing treatment option for chronic hand eczema in patients who require prolonged treatment with topical corticosteroids to maintain remission and as an alternative to topical corticosteroids in patients with contact allergy to topical corticosteroids [<a href="#rid59">59,60</a>]. Limited data support the use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment, but not <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream, for hand eczema:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small, randomized trial of 30 patients with allergic contact hand eczema, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment appeared similarly effective as <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate 0.1% ointment in reducing erythema, infiltration, vesiculation, desquamation, fissuring, and itching at three months [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small, uncontrolled study of 29 patients with occupational chronic hand dermatitis treated with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment for four weeks, 12 patients were clear of eczema at the end of the study [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 652 patients with mild to moderate chronic hand dermatitis were treated with <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream or vehicle twice daily with overnight occlusion for six weeks [<a href="#rid61">61</a>]. At the end of the study, the proportions of patients achieving the primary end point (Investigator Global Assessment score of 0 or 1 [clear/almost clear]) were similar in the pimecrolimus and vehicle groups (30 versus 23 percent, respectively).</p><p></p><p class="headingAnchor" id="H136930332"><span class="h2">Severe/recalcitrant disease</span><span class="headingEndMark"> — </span>Patients with severe or recalcitrant hand eczema that does not respond to superpotent topical corticosteroids may require systemic therapies, including oral corticosteroids, immunosuppressants, and retinoids, or phototherapy with narrowband ultraviolet B (NBUVB) or psoralen plus ultraviolet A (PUVA) [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p class="headingAnchor" id="H1603535544"><span class="h3">Treatment of secondary bacterial infection</span><span class="headingEndMark"> — </span>Secondary bacterial infection, usually with <em>Staphylococcus aureus</em>,<em> </em>may be associated with recalcitrant disease and unexplained failure to respond to treatment. Clinical signs of bacterial superinfection include weeping, pustules, and honey-colored crusting  (<a class="graphic graphic_picture graphicRef83006" href="/z/d/graphic/83006.html" rel="external">picture 15</a>). A course of systemic antibiotics may be given to patients with clinical signs of bacterial superinfection. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Systemic antibiotics'</a>.)</p><p class="headingAnchor" id="H55983279"><span class="h3">Systemic therapy</span></p><p class="headingAnchor" id="H3075611267"><span class="h4">Short-term oral corticosteroids</span><span class="headingEndMark"> — </span>For patients with severe, disabling hand eczema that does not respond to superpotent topical corticosteroids, we suggest a short course of oral corticosteroids to achieve rapid improvement while continuing regular emollient use. (See <a class="local">'Emollients/moisturizers'</a> above.)</p><p>Treatment is started with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent dose of other systemic corticosteroids  (<a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">table 3</a>)) at a dose of 0.5 to 1 mg/kg per day (maximum 60 mg per day) for seven days. The dose may be tapered and discontinued over the following two weeks. Daily treatment with superpotent topical corticosteroids should be resumed as oral corticosteroids are tapered off to avoid a rebound flare up. Topical corticosteroid treatment should be continued for a few weeks after oral corticosteroids are discontinued and then followed by maintenance intermittent therapy, as described above. (See <a class="local">'Mild to moderate disease'</a> above.)</p><p>There are no randomized trials evaluating the efficacy of oral corticosteroids for severe hand eczema. However, in clinical practice, they are beneficial in inducing rapid improvement in most patients with extensive allergic contact dermatitis or acute flares of atopic dermatitis. (See  <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">"Management of allergic contact dermatitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H2984566467"><span class="h4">Alitretinoin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">Alitretinoin</a> (9-cis-retinoic acid) is an oral retinoid with anti-inflammatory, immunomodulatory, antiproliferative, and apoptotic effects [<a href="#rid63">63</a>]. It is licensed in Europe and Canada for the treatment of severe chronic hand eczema that is unresponsive to potent topical corticosteroids but is not available in the United States.</p><p>Evidence from a few randomized trials supports the use of <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> for hand eczema [<a href="#rid39">39</a>]. In one study, 1032 patients with severe chronic hand eczema unresponsive to topical steroids were randomized to receive alitretinoin 30 or 10 mg per day or placebo for 12 to 24 weeks [<a href="#rid35">35</a>]. All patients were given an emollient cream and instructed to apply it frequently [<a href="#rid35">35</a>]. After 24 weeks, a greater proportion of patients achieved the primary end point of clear or almost clear hands in the alitretinoin 30 and 10 mg groups than those in the placebo group (48, 28, and 17 percent, respectively). Headache was the most frequent adverse effect of alitretinoin. Serious adverse events were rare, but alitretinoin was associated with increases in both total cholesterol and triglycerides.</p><p>As are all oral retinoids, <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a> is teratogenic. Female patients of childbearing potential must commit to the use of at least one form of effective contraception for at least one month prior to starting alitretinoin therapy, during therapy, and for one month after therapy and have a pregnancy test each month during treatment.</p><p class="headingAnchor" id="H946967487"><span class="h4">Other therapies</span><span class="headingEndMark"> — </span>Conventional immunosuppressants (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, cyclosporin, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) have been occasionally used in the management of patients with severe hand eczema [<a href="#rid64">64</a>]. However, there is insufficient evidence of benefit from high-quality studies to suggest their use in refractory cases. In a six-week, randomized trial including 41 patients with chronic hand eczema, oral cyclosporin 3 mg/kg per day was equally effective as topical <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate in reducing the baseline disease activity score (average reduction 43 and 42 percent, respectively) [<a href="#rid64">64</a>].</p><p><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, an interleukin (IL) 4/IL-13 receptor antagonist approved for the treatment of atopic dermatitis, has been reported as effective in improving nonatopic chronic hand eczema as well as isolated atopic hand eczema in a few patients [<a href="#rid65">65-69</a>].</p><p class="headingAnchor" id="H55983286"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>For patients with severe or recalcitrant hand eczema for whom oral corticosteroids are contraindicated or patients who prefer not using oral corticosteroids, we suggest local NBUVB phototherapy or topical PUVA therapy. Phototherapy is administered two to three times per week for at least 12 weeks. Patients should continue using emollients liberally. (See <a class="local">'Emollients/moisturizers'</a> above.)</p><p>Adverse effects of phototherapy include erythema, pruritus, hyperpigmentation, and increased risk of skin cancer. Nausea is a potential adverse effect of oral PUVA. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p>The use of phototherapy for patients with chronic hand eczema is largely supported by its use in the treatment of other inflammatory dermatoses. However, there are a few small clinical trials that have demonstrated clinical improvement with PUVA or NBUVB in patients with hand or palmoplantar eczema of various etiologies [<a href="#rid70">70-72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a left-to-right comparison study, 15 patients with chronic hand eczema were treated with local NBUVB or topical PUVA [<a href="#rid70">70</a>]. Complete clearance or marked clinical improvement (defined as 75 percent improvement in the baseline severity score) occurred in the NBUVB phototherapy-treated side in 11 of 12 patients and in the PUVA-treated side in 10 of 12 patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 60 patients with hand eczema unresponsive to super high-potency topical corticosteroids were treated with topical PUVA or NBUVB twice weekly for 12 weeks [<a href="#rid73">73</a>]. At the end of the study, 43 percent of patients in the PUVA group and 23 percent of patients in the NBUVB group achieved the primary outcome of a Physician Global Assessment (PGA) score of 0 or 1 (clear/almost clear).</p><p></p><p class="headingAnchor" id="H3985483632"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Delgocitinib is a small molecule pan-Janus kinase (JAK) inhibitor that inhibits the activation of innate and adaptive immune cells and inhibits T helper (Th)1-, Th2-, Th17-, and Th22-type inflammatory responses [<a href="#rid74">74</a>]. In a small, randomized, eight-week, phase 2a trial, topical delgocitinib 30 mg/g cream showed efficacy in improving chronic hand eczema [<a href="#rid75">75</a>]. In a subsequent phase 2b, randomized trial that included 258 patients with chronic hand eczema, more patients in the delgocitinib cream 8 mg/g and 20 mg/g groups achieved an Investigator Global Assessment score of clear/almost clear at 16 weeks compared with patients in the vehicle group (37 and 38 percent versus 8 percent, respectively) [<a href="#rid76">76</a>]. Treatment was generally well tolerated. Adverse events, including nasopharyngitis, eczema worsening, and headache, occurred with similar frequency in the active treatment and placebo groups (68 and 60 percent, respectively); were in most cases mild or moderate; and considered unrelated to treatment. No adverse event was suggestive of systemic exposure.</p><p class="headingAnchor" id="H506386567"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Hand eczema often has a very prolonged course. The reported average duration is approximately 12 years [<a href="#rid77">77,78</a>]. Moderate to severe eczema at initial examination, history of childhood eczema, and age younger than 20 years at diagnosis are the strong predictors of persistent disease [<a href="#rid79">79,80</a>]. Cigarette smoking also appears to be an unfavorable prognostic factor [<a href="#rid81">81,82</a>].</p><p>Chronic hand eczema may have significant psychosocial consequences, such as social stigma, long-term sick leaves, involuntary job rotation, and early retirement, and a profound impact on quality of life [<a href="#rid83">83-87</a>].</p><p class="headingAnchor" id="H826564358"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113033.html" rel="external">"Society guideline links: Contact dermatitis"</a>.)</p><p class="headingAnchor" id="H506386573"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Hand eczema, or hand dermatitis, is a common, inflammatory disorder involving skin of the hands that affects approximately 4 percent of the general population. It is also the most frequent occupational skin disease, with an incidence of 0.7 to 1.5 cases per 1000 workers per year. Hand eczema is especially common among workers exposed to "wet work," such as health care workers, food handlers, and hairdressers. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – In the acute stage, hand eczema typically presents with erythema, edema, weeping, and vesiculation  (<a class="graphic graphic_picture graphicRef95749 graphicRef82993" href="/z/d/graphic/95749.html" rel="external">picture 2A-B</a>). As lesions become subacute or chronic, scaling, thickening, and fissuring of the skin become the predominant clinical signs  (<a class="graphic graphic_picture graphicRef59959" href="/z/d/graphic/59959.html" rel="external">picture 3A</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of hand eczema is based upon a detailed history, physical examination, and patch testing. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of chronic hand eczema involves patient education about avoidance of irritants and allergens, skin protection measures, and anti-inflammatory therapy (see <a class="local">'General principles'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate disease</strong> – For patients with mild to moderate chronic hand eczema, we suggest high-potency or super high-potency topical corticosteroids (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) as a first-line treatment rather than lower-potency topical corticosteroids or topical calcineurin inhibitors (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For all patients with chronic hand eczema, we suggest the use of emollients (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These should be applied liberally multiple times per day. After induction of remission, we suggest maintenance intermittent therapy with a super high-potency or high-potency topical corticosteroid (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> can be used as a steroid-sparing treatment option for chronic hand eczema and as an alternative to topical corticosteroids in patients with contact allergy to topical corticosteroids. (See <a class="local">'Mild to moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe, recalcitrant disease</strong> – For patients with severe, recalcitrant hand eczema that does not respond to superpotent topical corticosteroids, we suggest a short course of oral corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative treatments include phototherapy, <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">alitretinoin</a>, or oral immunosuppressants (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, cyclosporin, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>). Alitretinoin is licensed in Europe and Canada for the treatment of severe chronic hand eczema unresponsive to potent topical corticosteroids but is not available in the United States. Because secondary bacterial infection, usually with <em>Staphylococcus aureus</em>,<em> </em>may be associated with recalcitrant disease and unexplained failure to respond to treatment, a course of systemic antibiotics may be given to patients with clinical signs of bacterial superinfection (eg, weeping, pustules, honey-colored crusting). (See <a class="local">'Severe/recalcitrant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Hand eczema often has a very prolonged course and may have significant psychosocial consequences, such as social stigma, long-term sick leaves, and job loss. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Coenraads PJ. Hand eczema. N Engl J Med 2012; 367:1829.</a></li><li><a class="nounderline abstract_t">Diepgen TL, Elsner P, Schliemann S, et al. Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges 2009; 7 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Fowler J. Chronic hand eczema: a prevalent and challenging skin condition. Cutis 2008; 82:4.</a></li><li><a class="nounderline abstract_t">Quaade AS, Simonsen AB, Halling AS, et al. Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis. Contact Dermatitis 2021; 84:361.</a></li><li><a class="nounderline abstract_t">Mortz CG, Bindslev-Jensen C, Andersen KE. Hand eczema in The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS): prevalence, incidence and risk factors from adolescence to adulthood. Br J Dermatol 2014; 171:313.</a></li><li><a class="nounderline abstract_t">Johannisson A, Pontén A, Svensson Å. Prevalence, incidence and predictive factors for hand eczema in young adults - a follow-up study. BMC Dermatol 2013; 13:14.</a></li><li><a class="nounderline abstract_t">Wang J, Tischer C, Standl M, et al. Lifetime prevalence and determinants of hand eczema in an adolescent population in Germany: 15-year follow-up of the LISA cohort study. J Eur Acad Dermatol Venereol 2022; 36:547.</a></li><li><a class="nounderline abstract_t">Diepgen TL. Occupational skin-disease data in Europe. Int Arch Occup Environ Health 2003; 76:331.</a></li><li><a class="nounderline abstract_t">Sedeh FB, Michaelsdóttir TE, Jemec GBE, et al. Prevalence, risk factors, and prevention of occupational contact dermatitis among professional cleaners: a systematic review. Int Arch Occup Environ Health 2023; 96:345.</a></li><li><a class="nounderline abstract_t">Ibler KS, Jemec GB, Flyvholm MA, et al. Hand eczema: prevalence and risk factors of hand eczema in a population of 2274 healthcare workers. Contact Dermatitis 2012; 67:200.</a></li><li><a class="nounderline abstract_t">Luk NM, Lee HC, Luk CK, et al. Hand eczema among Hong Kong nurses: a self-report questionnaire survey conducted in a regional hospital. Contact Dermatitis 2011; 65:329.</a></li><li><a class="nounderline abstract_t">Havmose MS, Kezic S, Uter W, et al. Prevalence and incidence of hand eczema in hairdressers-A systematic review and meta-analysis of the published literature from 2000-2021. Contact Dermatitis 2022; 86:254.</a></li><li><a class="nounderline abstract_t">Lysdal SH, Søsted H, Johansen JD. Do hairdressers in Denmark have their hand eczema reported as an occupational disease? Results from a register-based questionnaire study. Contact Dermatitis 2012; 66:72.</a></li><li><a class="nounderline abstract_t">Koskelo M, Sinikumpu SP, Jokelainen J, Huilaja L. Risk factors of hand eczema: A population-based study among 900 subjects. Contact Dermatitis 2022; 87:485.</a></li><li><a class="nounderline abstract_t">Loman L, Politiek K, Schuttelaar MLA. Smoking and obesity are associated with chronic hand eczema and severity of hand eczema: Data from the Dutch general population. Contact Dermatitis 2022; 87:103.</a></li><li><a class="nounderline abstract_t">Loh EW, Yew YW. Hand hygiene and hand eczema: A systematic review and meta-analysis. Contact Dermatitis 2022; 87:303.</a></li><li><a class="nounderline abstract_t">de Jongh CM, Khrenova L, Verberk MM, et al. Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. Br J Dermatol 2008; 159:621.</a></li><li><a class="nounderline abstract_t">Thyssen JP, Linneberg A, Ross-Hansen K, et al. Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis. Contact Dermatitis 2013; 68:273.</a></li><li><a class="nounderline abstract_t">Fartasch M, Taeger D, Broding HC, et al. Evidence of increased skin irritation after wet work: impact of water exposure and occlusion. Contact Dermatitis 2012; 67:217.</a></li><li><a class="nounderline abstract_t">Hamnerius N, Svedman C, Bergendorff O, et al. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol 2018; 178:452.</a></li><li><a class="nounderline abstract_t">Uter W, Pfahlberg A, Gefeller O, Schwanitz HJ. Risk of hand dermatitis among hairdressers versus office workers. Scand J Work Environ Health 1999; 25:450.</a></li><li><a class="nounderline abstract_t">Scalone L, Cortesi PA, Mantovani LG, et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. Br J Dermatol 2015; 172:187.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Warshaw EM, Atwater AR, et al. Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016. J Am Acad Dermatol 2021; 84:989.</a></li><li><a class="nounderline abstract_t">Levin C, Warshaw E. Protein contact dermatitis: allergens, pathogenesis, and management. Dermatitis 2008; 19:241.</a></li><li><a class="nounderline abstract_t">Amaro C, Goossens A. Immunological occupational contact urticaria and contact dermatitis from proteins: a review. Contact Dermatitis 2008; 58:67.</a></li><li><a class="nounderline abstract_t">Vester L, Thyssen JP, Menné T, Johansen JD. Consequences of occupational food-related hand dermatoses with a focus on protein contact dermatitis. Contact Dermatitis 2012; 67:328.</a></li><li><a class="nounderline abstract_t">Barbaud A, Poreaux C, Penven E, Waton J. Occupational protein contact dermatitis. Eur J Dermatol 2015; 25:527.</a></li><li><a class="nounderline abstract_t">Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol 2015; 29:2417.</a></li><li><a class="nounderline abstract_t">Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86:357.</a></li><li><a class="nounderline abstract_t">Menné T, Johansen JD, Sommerlund M, et al. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis 2011; 65:3.</a></li><li><a class="nounderline abstract_t">Alavi A, Skotnicki S, Sussman G, Sibbald RG. Diagnosis and treatment of hand dermatitis. Adv Skin Wound Care 2012; 25:371.</a></li><li><a class="nounderline abstract_t">Tirumalae R. Psoriasiform dermatoses: microscopic approach. Indian J Dermatol 2013; 58:290.</a></li><li><a class="nounderline abstract_t">Agner T, Jungersted JM, Coenraads PJ, Diepgen T. Comparison of four methods for assessment of severity of hand eczema. Contact Dermatitis 2013; 69:107.</a></li><li><a class="nounderline abstract_t">Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol 2005; 152:302.</a></li><li><a class="nounderline abstract_t">Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158:808.</a></li><li><a class="nounderline abstract_t">Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol 2005; 152:296.</a></li><li><a class="nounderline abstract_t">Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9:169.</a></li><li><a class="nounderline abstract_t">Strock D, Maghfour J, Dellavalle RP. From the Cochrane Library: Interventions for hand eczema. J Am Acad Dermatol 2022; 86:e31.</a></li><li><a class="nounderline abstract_t">Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev 2019; 4:CD004055.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Guttman-Yassky E, Agner T, et al. Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. Dermatitis 2021; 32:319.</a></li><li><a class="nounderline abstract_t">Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema--short version. J Dtsch Dermatol Ges 2015; 13:77.</a></li><li><a class="nounderline abstract_t">Mollerup A, Johansen JD, Thing LF. Knowledge, attitudes and behaviour in everyday life with chronic hand eczema: a qualitative study. Br J Dermatol 2013; 169:1056.</a></li><li><a class="nounderline abstract_t">Ibler KS, Jemec GB, Diepgen TL, et al. Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial. BMJ 2012; 345:e7822.</a></li><li><a class="nounderline abstract_t">van Gils RF, Boot CR, Knol DL, et al. The effectiveness of integrated care for patients with hand eczema: results of a randomized, controlled trial. Contact Dermatitis 2012; 66:197.</a></li><li><a class="nounderline abstract_t">Dulon M, Pohrt U, Skudlik C, Nienhaus A. Prevention of occupational skin disease: a workplace intervention study in geriatric nurses. Br J Dermatol 2009; 161:337.</a></li><li><a class="nounderline abstract_t">Ridd MJ, Santer M, MacNeill SJ, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health 2022; 6:522.</a></li><li><a class="nounderline abstract_t">Löffler H, Kampf G, Schmermund D, Maibach HI. How irritant is alcohol? Br J Dermatol 2007; 157:74.</a></li><li><a class="nounderline abstract_t">Kampf G, Löffler H. Prevention of irritant contact dermatitis among health care workers by using evidence-based hand hygiene practices: a review. Ind Health 2007; 45:645.</a></li><li class="breakAll">Estlander T, Jolanki R, Kanerva L. Protective gloves. In: Hand Eczema, Menné T, Maibach HI (Eds), CRC Press, Boca Raton, Florida 1994.</li><li><a class="nounderline abstract_t">Teichmann A, Jacobi U, Waibler E, et al. An in vivo model to evaluate the efficacy of barrier creams on the level of skin penetration of chemicals. Contact Dermatitis 2006; 54:5.</a></li><li><a class="nounderline abstract_t">Berndt U, Wigger-Alberti W, Gabard B, Elsner P. Efficacy of a barrier cream and its vehicle as protective measures against occupational irritant contact dermatitis. Contact Dermatitis 2000; 42:77.</a></li><li><a class="nounderline abstract_t">Kucharekova M, Van De Kerkhof PC, Van Der Valk PG. A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based emollient as adjunct in the treatment of chronic hand dermatitis. Contact Dermatitis 2003; 48:293.</a></li><li><a class="nounderline abstract_t">McCormick RD, Buchman TL, Maki DG. Double-blind, randomized trial of scheduled use of a novel barrier cream and an oil-containing lotion for protecting the hands of health care workers. Am J Infect Control 2000; 28:302.</a></li><li><a class="nounderline abstract_t">Bauer A, Rönsch H, Elsner P, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2018; 4:CD004414.</a></li><li><a class="nounderline abstract_t">Lodén M, Wirén K, Smerud K, et al. Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study. Acta Derm Venereol 2010; 90:602.</a></li><li><a class="nounderline abstract_t">Draelos ZD. New treatments for restoring impaired epidermal barrier permeability: skin barrier repair creams. Clin Dermatol 2012; 30:345.</a></li><li><a class="nounderline abstract_t">Kircik LH, Eastman WJ, Gwazdauskas J. A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis. J Drugs Dermatol 2013; 12:328.</a></li><li><a class="nounderline abstract_t">Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999; 140:882.</a></li><li><a class="nounderline abstract_t">Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008; 58:299.</a></li><li><a class="nounderline abstract_t">Katsarou A, Makris M, Papagiannaki K, et al. Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol 2012; 22:192.</a></li><li><a class="nounderline abstract_t">Hordinsky M, Fleischer A, Rivers JK, et al. Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. Dermatology 2010; 221:71.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol 2010; 24 Suppl 3:1.</a></li><li><a class="nounderline abstract_t">Bubna AK. Alitretinoin in Dermatology-An Update. Indian J Dermatol 2015; 60:520.</a></li><li><a class="nounderline abstract_t">Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 1996; 76:371.</a></li><li><a class="nounderline abstract_t">Loman L, Diercks GFH, Schuttelaar MLA. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis 2021; 84:124.</a></li><li><a class="nounderline abstract_t">Zhu GA, Honari G, Ko JM, et al. Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report. JAAD Case Rep 2020; 6:296.</a></li><li><a class="nounderline abstract_t">Lee N, Chipalkatti N, Zancanaro P, et al. A Retrospective Review of Dupilumab for Hand Dermatitis. Dermatology 2019; 235:187.</a></li><li><a class="nounderline abstract_t">Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol 2018; 79:167.</a></li><li><a class="nounderline abstract_t">Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema. JAMA Dermatol 2018; 154:969.</a></li><li><a class="nounderline abstract_t">Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.</a></li><li><a class="nounderline abstract_t">Schempp CM, Müller H, Czech W, et al. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol 1997; 36:733.</a></li><li><a class="nounderline abstract_t">Tegner E, Thelin I. PUVA treatment of chronic eczematous dermatitis of the palms and soles. Acta Derm Venereol 1985; 65:451.</a></li><li><a class="nounderline abstract_t">Brass D, Fouweather T, Stocken DD, et al. An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. Br J Dermatol 2018; 179:63.</a></li><li><a class="nounderline abstract_t">Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Dermatol 2018; 27:22.</a></li><li><a class="nounderline abstract_t">Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol 2020; 182:1103.</a></li><li><a class="nounderline abstract_t">Worm M, Thyssen JP, Schliemann S, et al. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Br J Dermatol 2022; 187:42.</a></li><li><a class="nounderline abstract_t">Anveden I, Wrangsjö K, Järvholm B, Meding B. Self-reported skin exposure -- a population-based study. Contact Dermatitis 2006; 54:272.</a></li><li><a class="nounderline abstract_t">Meding B, Swanbeck G. Epidemiology of different types of hand eczema in an industrial city. Acta Derm Venereol 1989; 69:227.</a></li><li><a class="nounderline abstract_t">Thyssen JP, Johansen JD, Linneberg A, Menné T. The epidemiology of hand eczema in the general population--prevalence and main findings. Contact Dermatitis 2010; 62:75.</a></li><li><a class="nounderline abstract_t">Meding B, Wrangsjö K, Järvholm B. Fifteen-year follow-up of hand eczema: predictive factors. J Invest Dermatol 2005; 124:893.</a></li><li><a class="nounderline abstract_t">Brans R, Skudlik C, Weisshaar E, et al. Association between tobacco smoking and prognosis of occupational hand eczema: a prospective cohort study. Br J Dermatol 2014; 171:1108.</a></li><li><a class="nounderline abstract_t">Olesen CM, Agner T, Ebbehøj NE, Carøe TK. Factors influencing prognosis for occupational hand eczema: new trends. Br J Dermatol 2019; 181:1280.</a></li><li><a class="nounderline abstract_t">Mollerup A, Veien NK, Johansen JD. Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial. BMC Dermatol 2012; 12:6.</a></li><li><a class="nounderline abstract_t">Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis 2008; 58:330.</a></li><li><a class="nounderline abstract_t">Meding B, Wrangsjö K, Järvholm B. Fifteen-year follow-up of hand eczema: persistence and consequences. Br J Dermatol 2005; 152:975.</a></li><li><a class="nounderline abstract_t">Cvetkovski RS, Zachariae R, Jensen H, et al. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis 2006; 54:106.</a></li><li><a class="nounderline abstract_t">Petersen AH, Johansen JD, Hald M. Hand eczema—prognosis and consequences: a 7-year follow-up study. Br J Dermatol 2014; 171:1428.</a></li></ol></div><div id="topicVersionRevision">Topic 13658 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134383" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19522920" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19202670" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic hand eczema: a prevalent and challenging skin condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33548072" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628258" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hand eczema in The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS): prevalence, incidence and risk factors from adolescence to adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24164871" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence, incidence and predictive factors for hand eczema in young adults - a follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34779040" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lifetime prevalence and determinants of hand eczema in an adolescent population in Germany: 15-year follow-up of the LISA cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690490" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Occupational skin-disease data in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409350" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence, risk factors, and prevention of occupational contact dermatitis among professional cleaners: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22624885" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hand eczema: prevalence and risk factors of hand eczema in a population of 2274 healthcare workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21831240" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hand eczema among Hong Kong nurses: a self-report questionnaire survey conducted in a regional hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35038179" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence and incidence of hand eczema in hairdressers-A systematic review and meta-analysis of the published literature from 2000-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085159" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Do hairdressers in Denmark have their hand eczema reported as an occupational disease? Results from a register-based questionnaire study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980390" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk factors of hand eczema: A population-based study among 900 subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35292987" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Smoking and obesity are associated with chronic hand eczema and severity of hand eczema: Data from the Dutch general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460528" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hand hygiene and hand eczema: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18637008" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23343419" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Filaggrin mutations are strongly associated with contact sensitization in individuals with dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591550" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence of increased skin irritation after wet work: impact of water exposure and occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28722122" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Wet work exposure and hand eczema among healthcare workers: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10569466" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of hand dermatitis among hairdressers versus office workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24974982" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33259878" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18845114" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Protein contact dermatitis: allergens, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186738" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Immunological occupational contact urticaria and contact dermatitis from proteins: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22624860" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Consequences of occupational food-related hand dermatoses with a focus on protein contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26242922" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Occupational protein contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371368" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Classification of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34971008" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guidelines for diagnosis, prevention, and treatment of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658053" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820963" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and treatment of hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23919000" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Psoriasiform dermatoses: microscopic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869730" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of four methods for assessment of severity of hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727643" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294310" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727642" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15083785" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 10 years experience of the Dermatology Life Quality Index (DLQI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34606772" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : From the Cochrane Library: Interventions for hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31025714" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interventions for hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32991335" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640512" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Guidelines for diagnosis, prevention and treatment of hand eczema--short version.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889257" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Knowledge, attitudes and behaviour in everyday life with chronic hand eczema: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23236031" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404194" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effectiveness of integrated care for patients with hand eczema: results of a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438864" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevention of occupational skin disease: a workplace intervention study in geriatric nurses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35617974" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578437" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : How irritant is alcohol?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057807" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevention of irritant contact dermatitis among health care workers by using evidence-based hand hygiene practices: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057807" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevention of irritant contact dermatitis among health care workers by using evidence-based hand hygiene practices: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426286" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An in vivo model to evaluate the efficacy of barrier creams on the level of skin penetration of chemicals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703628" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of a barrier cream and its vehicle as protective measures against occupational irritant contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531866" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized comparison of an emollient containing skin-related lipids with a petrolatum-based emollient as adjunct in the treatment of chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926708" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Double-blind, randomized trial of scheduled use of a novel barrier cream and an oil-containing lotion for protecting the hands of health care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29708265" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interventions for preventing occupational irritant hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057743" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema. An open, randomized, prospective, parallel group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22507050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : New treatments for restoring impaired epidermal barrier permeability: skin barrier repair creams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545917" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A randomized, double-blind phase 4 study of the efficacy and safety of ethanol-free clobetasol propionate foam, 0.05%, vs vehicle foam in the treatment of chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354026" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term, intermittent treatment of chronic hand eczema with mometasone furoate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416762" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407003" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693804" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20443999" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Redefining treatment options in chronic hand eczema (CHE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538721" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Alitretinoin in Dermatology-An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8891011" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32864776" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32258302" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30726838" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A Retrospective Review of Dupilumab for Hand Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29535032" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Dupilumab for hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971331" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dupilumab Treatment of Very Severe Refractory Atopic Hand Eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254029" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146535" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2416177" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : PUVA treatment of chronic eczematous dermatitis of the palms and soles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29235664" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423239" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31466119" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35084738" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16689812" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Self-reported skin exposure -- a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2566226" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Epidemiology of different types of hand eczema in an industrial city.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20136890" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The epidemiology of hand eczema in the general population--prevalence and main findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854027" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fifteen-year follow-up of hand eczema: predictive factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24909920" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association between tobacco smoking and prognosis of occupational hand eczema: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30851194" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Factors influencing prognosis for occupational hand eczema: new trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691871" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503681" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hand eczema: causes, course, and prognosis I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888155" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fifteen-year follow-up of hand eczema: persistence and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487283" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Quality of life and depression in a population of occupational hand eczema patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156938" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hand eczema—prognosis and consequences: a 7-year follow-up study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
